{"id":"https://openalex.org/W4402065425","doi":"https://doi.org/10.3389/fonc.2024.1427452","title":"PD-L1 expression and correlation with outcome in muscle-invasive and metastatic urothelial carcinoma: review and critical discussion","display_name":"PD-L1 expression and correlation with outcome in muscle-invasive and metastatic urothelial carcinoma: review and critical discussion","publication_year":2024,"publication_date":"2024-08-30","ids":{"openalex":"https://openalex.org/W4402065425","doi":"https://doi.org/10.3389/fonc.2024.1427452","pmid":"https://pubmed.ncbi.nlm.nih.gov/39281379","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/11393474"},"language":"en","primary_location":{"id":"doi:10.3389/fonc.2024.1427452","doi":"https://doi.org/10.3389/fonc.2024.1427452","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2024.1427452","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1427452/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","datacite","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1427452/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027754541","display_name":"T\u00e4mer El Saadany","orcid":"https://orcid.org/0000-0001-9953-6865","observed_orcids":["https://orcid.org/0000-0001-9953-6865"]},"institutions":[{"id":"https://openalex.org/I4210148531","display_name":"Kantonsspital Graub\u00fcnden","ror":"https://ror.org/04wpn1218","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210148531"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"T\u00e4mer El Saadany","raw_affiliation_strings":["Division of Oncology/Hematology, Cantonal Hospital Graub\u00fcnden, Chur, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Oncology/Hematology, Cantonal Hospital Graub\u00fcnden, Chur, Switzerland","institution_ids":["https://openalex.org/I4210148531"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Anja Lorch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100468","display_name":"University Hospital Zurich","ror":"https://ror.org/01462r250","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210100468"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Anja Lorch","raw_affiliation_strings":["Department of Medical Oncology and Hematology, University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland","institution_ids":["https://openalex.org/I4210100468"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083920381","display_name":"Matthew I. Milowsky","orcid":"https://orcid.org/0000-0002-8965-8129","observed_orcids":["https://orcid.org/0000-0002-8965-8129"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew I. Milowsky","raw_affiliation_strings":["Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102945842","display_name":"Ursula Maria Vogl","orcid":"https://orcid.org/0000-0003-2015-6080","observed_orcids":["https://orcid.org/0000-0003-2015-6080"]},"institutions":[{"id":"https://openalex.org/I4210095212","display_name":"Ente Ospedaliero Cantonale","ror":"https://ror.org/00sh19a92","country_code":"CH","type":"other","lineage":["https://openalex.org/I4210095212"]},{"id":"https://openalex.org/I4404532900","display_name":"Istituto Oncologico della Svizzera Italiana","ror":"https://ror.org/04tty5b50","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210095212","https://openalex.org/I4404532900"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Ursula Maria Vogl","raw_affiliation_strings":["IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland","institution_ids":["https://openalex.org/I4210095212","https://openalex.org/I4404532900"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050931392","display_name":"Richard L. Cathomas","orcid":"https://orcid.org/0000-0002-9677-9885","observed_orcids":["https://orcid.org/0000-0002-9677-9885"]},"institutions":[{"id":"https://openalex.org/I4210148531","display_name":"Kantonsspital Graub\u00fcnden","ror":"https://ror.org/04wpn1218","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210148531"]}],"countries":["CH"],"is_corresponding":true,"raw_author_name":"Richard Cathomas","raw_affiliation_strings":["Division of Oncology/Hematology, Cantonal Hospital Graub\u00fcnden, Chur, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Oncology/Hematology, Cantonal Hospital Graub\u00fcnden, Chur, Switzerland","institution_ids":["https://openalex.org/I4210148531"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5050931392"],"corresponding_institution_ids":["https://openalex.org/I4210148531"],"apc_list":{"value":3295,"currency":"USD","value_usd":3295},"apc_paid":{"value":3295,"currency":"USD","value_usd":3295},"fwci":0.7794,"has_fulltext":true,"cited_by_count":2,"citation_normalized_percentile":{"value":0.71519035,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":95},"biblio":{"volume":"14","issue":null,"first_page":"1427452","last_page":"1427452"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.6845999956130981,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.6845999956130981,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.31049999594688416,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12695","display_name":"Urinary and Genital Oncology Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.9980000257492065},{"id":"https://openalex.org/keywords/urothelial-carcinoma","display_name":"urothelial carcinoma","score":0.8820000290870667},{"id":"https://openalex.org/keywords/muscle-invasive-bladder-cancer","display_name":"muscle-invasive bladder cancer","score":0.8790000081062317},{"id":"https://openalex.org/keywords/metastatic-bladder-cancer","display_name":"metastatic bladder cancer","score":0.9419999718666077},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8339999914169312},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.8870000243186951},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":1.0},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":1.0},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.8500000238418579},{"id":"https://openalex.org/keywords/pd-1-expression","display_name":"PD-1 expression","score":0.8209999799728394},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.6819999814033508},{"id":"https://openalex.org/keywords/regulatory-approval","display_name":"regulatory approval","score":0.7089999914169312}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.8762552738189697},{"id":"https://openalex.org/C2911057145","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Metastatic Urothelial Carcinoma","level":5,"score":0.8372172117233276},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.7901105880737305},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.7877537608146667},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7439526915550232},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5947043299674988},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5613667368888855},{"id":"https://openalex.org/C204232928","wikidata":"https://www.wikidata.org/wiki/Q899285","display_name":"Immunohistochemistry","level":2,"score":0.49499577283859253},{"id":"https://openalex.org/C3019882237","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Urothelial carcinoma","level":4,"score":0.4646766781806946},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4376552104949951},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.3805849254131317},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3599923253059387},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.27440470457077026}],"mesh":[],"locations_count":9,"locations":[{"id":"doi:10.3389/fonc.2024.1427452","doi":"https://doi.org/10.3389/fonc.2024.1427452","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2024.1427452","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1427452/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:11393474","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11393474","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11393474/pdf/fonc-14-1427452.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Oncol","raw_type":"Text"},{"id":"pmid:39281379","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39281379","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in oncology","raw_type":"Journal Article"},{"id":"pmh:oai:www.zora.uzh.ch:264397","doi":null,"is_oa":true,"landing_page_url":"https://www.zora.uzh.ch/id/eprint/264397/1/ZORA_264397.pdf","pdf_url":"https://www.zora.uzh.ch/id/eprint/264397/1/ZORA_264397.pdf","source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"El Saadany, T\u00e4mer; Lorch, Anja; Milowsky, Matthew I; Vogl, Ursula Maria; Cathomas, Richard (2024). PD-L1 expression and correlation with outcome in muscle-invasive and metastatic urothelial carcinoma: review and critical discussion. Frontiers in Oncology, 14:1427452.","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:cdr.lib.unc.edu:cz30q747k","doi":null,"is_oa":true,"landing_page_url":"https://doi.org/10.17615/v3v4-ff16","pdf_url":"https://doi.org/10.17615/v3v4-ff16","source":{"id":"https://openalex.org/S4306401075","display_name":"Carolina Digital Repository (University of North Carolina at Chapel Hill)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I114027177","host_organization_name":"University of North Carolina at Chapel Hill","host_organization_lineage":["https://openalex.org/I114027177"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Oncology, 14","raw_type":"Article"},{"id":"pmh:oai:doaj.org/article:583522b4a83b49b2b68924c137d2bf22","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/583522b4a83b49b2b68924c137d2bf22","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Oncology, Vol 14 (2024)","raw_type":"article"},{"id":"pmh:oai:www.zora.uzh.ch:20.500.14742/222800","doi":null,"is_oa":true,"landing_page_url":"https://www.zora.uzh.ch/handle/20.500.14742/222800","pdf_url":null,"source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"El Saadany, T., Lorch, A., Milowsky, M. I., Vogl, U. M., & Cathomas, R. (2024). PD-L1 expression and correlation with outcome in muscle-invasive and metastatic urothelial carcinoma: review and critical discussion. Frontiers in Oncology, 14, 1427452. https://doi.org/10.3389/fonc.2024.1427452","raw_type":"Journal Article"},{"id":"doi:10.17615/v3v4-ff16","doi":"https://doi.org/10.17615/v3v4-ff16","is_oa":true,"landing_page_url":"https://doi.org/10.17615/v3v4-ff16","pdf_url":null,"source":{"id":"https://openalex.org/S7407051488","display_name":"UNC Libraries","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},{"id":"doi:10.5167/uzh-264397","doi":"https://doi.org/10.5167/uzh-264397","is_oa":true,"landing_page_url":"https://doi.org/10.5167/uzh-264397","pdf_url":null,"source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"}],"best_oa_location":{"id":"doi:10.3389/fonc.2024.1427452","doi":"https://doi.org/10.3389/fonc.2024.1427452","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2024.1427452","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1427452/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320315087","display_name":"Clovis Oncology","ror":"https://ror.org/04ps4d441"},{"id":"https://openalex.org/F4320316443","display_name":"Accuray","ror":"https://ror.org/0129gkf70"},{"id":"https://openalex.org/F4320317007","display_name":"Mirati Therapeutics","ror":"https://ror.org/01by01460"},{"id":"https://openalex.org/F4320318017","display_name":"Inselspital, Universit\u00e4tsspital Bern","ror":"https://ror.org/01q9sj412"},{"id":"https://openalex.org/F4320319266","display_name":"G1 Therapeutics","ror":"https://ror.org/048389405"},{"id":"https://openalex.org/F4320319515","display_name":"Seagen","ror":null},{"id":"https://openalex.org/F4320323024","display_name":"Astellas Pharma","ror":"https://ror.org/01cjash87"},{"id":"https://openalex.org/F4320328455","display_name":"Ipsen","ror":"https://ror.org/00d801g55"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4402065425.pdf","grobid_xml":"https://content.openalex.org/works/W4402065425.grobid-xml"},"referenced_works_count":20,"referenced_works":["https://openalex.org/W1971208896","https://openalex.org/W2559804019","https://openalex.org/W2588916311","https://openalex.org/W2777192533","https://openalex.org/W2895441403","https://openalex.org/W2910280410","https://openalex.org/W2988589394","https://openalex.org/W3024551702","https://openalex.org/W3036701611","https://openalex.org/W3087464965","https://openalex.org/W3087466624","https://openalex.org/W3134452282","https://openalex.org/W3138703636","https://openalex.org/W3156566103","https://openalex.org/W3163995648","https://openalex.org/W3164197656","https://openalex.org/W4213389115","https://openalex.org/W4386550249","https://openalex.org/W4387859553","https://openalex.org/W4391303721"],"related_works":["https://openalex.org/W2985932098","https://openalex.org/W3117168428","https://openalex.org/W2940428188","https://openalex.org/W6947578175","https://openalex.org/W2606258965","https://openalex.org/W3158881871","https://openalex.org/W3212938921","https://openalex.org/W4386378703","https://openalex.org/W4387609177","https://openalex.org/W3136760947"],"abstract_inverted_index":{"Immunotherapy":[0],"with":[1,96],"checkpoint":[2,69],"inhibitors":[3,70],"including":[4],"atezolizumab,":[5],"pembrolizumab":[6],"and":[7,20,34],"nivolumab":[8],"has":[9,26],"become":[10],"an":[11],"essential":[12],"pillar":[13],"in":[14,29,71],"the":[15,30,47,66,81,85,90,97,103],"management":[16],"of":[17,50,68,80,102],"muscle":[18],"invasive":[19],"metastatic":[21],"urothelial":[22,72],"carcinoma.":[23,73],"The":[24],"field":[25],"evolved":[27],"quickly":[28],"past":[31],"few":[32],"years":[33],"several":[35],"early":[36],"beliefs":[37],"have":[38,93],"recently":[39],"been":[40,94],"upended.":[41],"One":[42],"such":[43],"belief":[44],"relates":[45],"to":[46],"predictive":[48],"value":[49],"PD-L1":[51,59],"expression":[52,60,109],"based":[53,95],"on":[54,88],"immunohistochemistry.":[55],"Nevertheless,":[56],"requirements":[57],"for":[58],"from":[61,84],"regulatory":[62],"bodies":[63],"still":[64],"restrict":[65],"use":[67],"This":[74],"article":[75],"provides":[76],"a":[77,100],"critical":[78],"review":[79,101],"available":[82],"data":[83],"registration":[86],"trials":[87],"which":[89],"current":[91,104],"regulations":[92],"conclusion":[98],"that":[99],"approval":[105],"status":[106],"incorporating":[107],"PD-1":[108],"is":[110],"warranted.":[111]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2024-08-31T00:00:00"}